Hepatitis C Virus Infection Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Dongguan HEC TaiGen Biopharma, Cocrystal Pharma, Abbvie, Janssen

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hepatitis C Virus Infection pipeline constitutes 20+ key companies continuously working towards developing 20+ Hepatitis C Virus Infection treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Hepatitis C Virus Infection Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/hepatitis-c-virus-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hepatitis C Virus Infection Market.

The Hepatitis C Virus Infection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hepatitis C Virus Infection Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Hepatitis C Virus Infection treatment therapies with a considerable amount of success over the years.

*
Hepatitis C Virus Infection companies working in the treatment market are Dongguan HEC TaiGen Biopharmaceuticals, Cocrystal Pharma, Abbvie, Janssen Infectious Diseases, Gilead Sciences, Merck Sharp & Dohme LLC, Bristol-Myers Squibb, and others, are developing therapies for the Hepatitis C Virus Infection treatment

*
Emerging Hepatitis C Virus Infection therapies in the different phases of clinical trials are- TG-2349, CC-31244, Glecaprevir/Pibrentasvir (GLE/PIB), Simeprevir, LDV/SOF, EBR/GZR (50 mg/100 mg) FDC, Daclatasvir, and others are expected to have a significant impact on the Hepatitis C Virus Infection market in the coming years.

*
In April 2025, Boston-based Atea Pharmaceuticals announced the dosing of the first patient in its C-BEYOND Phase 3 trial, being conducted in the US and Canada. This study will assess the effectiveness of the combination of bemnifosbuvir and ruzasvir in adults with chronic hepatitis C virus (HCV), comparing it to the standard treatment regimen of sofosbuvir and velpatasvir. The company stated, "Enrolling our first patient in this global Phase 3 program marks a significant step forward in our efforts to develop a differentiated, next-generation therapy for HCV."

*
In March 2025, Atea Pharmaceuticals is preparing to initiate two parallel Phase 3 clinical trials to evaluate its investigational combination of bemnifosbuvir and ruzasvir in individuals with hepatitis C. One trial will be conducted in the U.S. and Canada, while the other will enroll participants at sites outside North America. Both studies will compare the experimental therapy to the approved hepatitis C treatment Epclusa (sofosbuvir/velpatasvir). Patient recruitment is expected to begin in April. These plans follow positive discussions with the U.S. Food and Drug Administration (FDA) in January, where encouraging results from a Phase 2 trial (NCT05904470) were reviewed.

*
In July 2024, The World Health Organization (WHO) has prequalified the first self-test for hepatitis C, a liver disease caused by the hepatitis C virus (HCV). HCV can lead to acute or chronic hepatitis, with symptoms ranging from mild illness to severe, lifelong conditions such as liver cancer and cirrhosis. The virus is bloodborne, and transmission often occurs through unsafe injection practices, inadequate healthcare procedures, blood transfusions, injection drug use, or contact involving blood exposure. Although no vaccine exists for HCV, antiviral treatments can effectively cure 95% of infections.

Hepatitis C Virus Infection Overview

Hepatitis C Virus (HCV) Infection is a liver disease caused by the hepatitis C virus. It spreads primarily through exposure to infected blood, often via shared needles, unscreened blood transfusions, or unsterilized medical equipment. HCV infection can be acute (short-term) or chronic (long-term). While acute cases may resolve spontaneously, chronic infection can lead to severe complications like liver fibrosis, cirrhosis, and liver cancer.

Get a Free Sample PDF Report to know more about Hepatitis C Virus Infection Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/hepatitis-c-virus-infection-pipeline-insight [https://www.delveinsight.com/report-store/hepatitis-c-virus-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Hepatitis C Virus Infection Drugs Under Different Phases of Clinical Development Include:

*
TG-2349: Dongguan HEC TaiGen Biopharmaceuticals

*
CC-31244: Cocrystal Pharma

*
Glecaprevir/Pibrentasvir (GLE/PIB): Abbvie

*
Simeprevir: Janssen Infectious Diseases

*
LDV/SOF: Gilead Sciences

*
EBR/GZR (50 mg/100 mg) FDC: Merck Sharp & Dohme LLC

*
Daclatasvir: Bristol-Myers Squibb

Hepatitis C Virus Infection Route of Administration

Hepatitis C Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Hepatitis C Virus Infection Molecule Type

Hepatitis C Virus Infection Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Hepatitis C Virus Infection Pipeline Therapeutics Assessment

*
Hepatitis C Virus Infection Assessment by Product Type

*
Hepatitis C Virus Infection By Stage and Product Type

*
Hepatitis C Virus Infection Assessment by Route of Administration

*
Hepatitis C Virus Infection By Stage and Route of Administration

*
Hepatitis C Virus Infection Assessment by Molecule Type

*
Hepatitis C Virus Infection by Stage and Molecule Type

DelveInsight's Hepatitis C Virus Infection Report covers around 20+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Hepatitis C Virus Infection product details are provided in the report. Download the Hepatitis C Virus Infection pipeline report to learn more about the emerging Hepatitis C Virus Infection therapies [https://www.delveinsight.com/sample-request/hepatitis-c-virus-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Hepatitis C Virus Infection Therapeutics Market include:

Key companies developing therapies for Hepatitis C Virus Infection are - Sunshine Lake Pharma Co., Ltd., GeneCure Biotechnologies, Biotron, Cocrystal Pharma, Genecure Biotechnologies Preclinical, iQur, Atea Pharmaceutical, Dongguan HEC TaiGen Biopharmaceuticals, Nanjing Sanhome Pharmaceutical, and others.

Hepatitis C Virus Infection Pipeline Analysis:

The Hepatitis C Virus Infection pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Hepatitis C Virus Infection with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatitis C Virus Infection Treatment.

*
Hepatitis C Virus Infection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Hepatitis C Virus Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatitis C Virus Infection market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hepatitis C Virus Infection drugs and therapies [https://www.delveinsight.com/sample-request/hepatitis-c-virus-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hepatitis C Virus Infection Pipeline Market Drivers

*
Rising Prevalence of HCV, Advancements in Antiviral Therapies, Global Health Initiatives, Improved Diagnostic Tools, Focus on Pan-genotypic Treatments, are some of the important factors that are fueling the Hepatitis C Virus Infection Market.

Hepatitis C Virus Infection Pipeline Market Barriers

*
However, High Treatment Costs, Lack of Vaccine, Asymptomatic Cases, Drug Resistance, Healthcare Infrastructure Gaps, and other factors are creating obstacles in the Hepatitis C Virus Infection Market growth.

Scope of Hepatitis C Virus Infection Pipeline Drug Insight

*
Coverage: Global

*
Key Hepatitis C Virus Infection Companies: Dongguan HEC TaiGen Biopharmaceuticals, Cocrystal Pharma, Abbvie, Janssen Infectious Diseases, Gilead Sciences, Merck Sharp & Dohme LLC, Bristol-Myers Squibb, and others

*
Key Hepatitis C Virus Infection Therapies: TG-2349, CC-31244, Glecaprevir/Pibrentasvir (GLE/PIB), Simeprevir, LDV/SOF, EBR/GZR (50 mg/100 mg) FDC, Daclatasvir, and others

*
Hepatitis C Virus Infection Therapeutic Assessment: Hepatitis C Virus Infection current marketed and Hepatitis C Virus Infection emerging therapies

*
Hepatitis C Virus Infection Market Dynamics: Hepatitis C Virus Infection market drivers and Hepatitis C Virus Infection market barriers

Request for Sample PDF Report for Hepatitis C Virus Infection Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/hepatitis-c-virus-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Hepatitis C Virus Infection Report Introduction

2. Hepatitis C Virus Infection Executive Summary

3. Hepatitis C Virus Infection Overview

4. Hepatitis C Virus Infection- Analytical Perspective In-depth Commercial Assessment

5. Hepatitis C Virus Infection Pipeline Therapeutics

6. Hepatitis C Virus Infection Late Stage Products (Phase II/III)

7. Hepatitis C Virus Infection Mid Stage Products (Phase II)

8. Hepatitis C Virus Infection Early Stage Products (Phase I)

9. Hepatitis C Virus Infection Preclinical Stage Products

10. Hepatitis C Virus Infection Therapeutics Assessment

11. Hepatitis C Virus Infection Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hepatitis C Virus Infection Key Companies

14. Hepatitis C Virus Infection Key Products

15. Hepatitis C Virus Infection Unmet Needs

16 . Hepatitis C Virus Infection Market Drivers and Barriers

17. Hepatitis C Virus Infection Future Perspectives and Conclusion

18. Hepatitis C Virus Infection Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hepatitis-c-virus-infection-pipeline-2025-key-companies-moa-roa-and-clinical-trials-evaluation-by-delveinsight-dongguan-hec-taigen-biopharma-cocrystal-pharma-abbvie-janssen]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.